Adult Participants With Elevated Lipoprotein(a)
Conditions
Brief summary
The purpose of this study is to evaluate the efficacy and safety of SYH2068 injection in patients with elevated lipoprotein(a).
Detailed description
This is a multicenter, randomized, double-blind, parallel, placebo-controlled Phase II clinical trial aimed at evaluating the efficacy, safety, immunogenicity, and pharmacokinetic characteristics of SYH2068 injection in adult participants with elevated lipoprotein(a). The study consists of a screening period and a treatment period.
Interventions
DRUGSYH2068 Dose 1
Administered by subcutaneous injection.
DRUGSYH2068 Dose 2
Administered by subcutaneous injection.
DRUGSYH2068 Dose 3
Administered by subcutaneous injection.
DRUGPlacebo
Administered by subcutaneous injection.
Sponsors
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Male or female participants ≥18 years of age; 2. Elevated Lp(a); 3. Participants who have used lipid-lowering drugs continue to use a stable dose, and those who have not used do not start new lipid-lowering drugs; 4. Presence of ASCVD or ASCVD risk stratification assessed as moderate or high risk; 5. Participants are able to understand and cooperate to complete this study, voluntarily participate in this study, and sign the ICF.
Exclusion criteria
1. Diseases that significantly affect Lp(a) during screening period, 2. Major or unstable cardiovascular events occurring from 3 months before signing the ICF to randomization; 3. Undergoing or expected to undergo peripheral arterial, coronary, or cerebrovascular revascularization surgery or other major surgery within 3 months prior to signing the ICF until randomization or during the study period; 4. NYHA class III-IV at the time of signing the ICF or LVEF \<40% during the screening period; 5. Type 1 diabetes or hereditary hemorrhagic disorder at screening; 6. History of malignant tumor or suspected malignancy within 5 years prior to screening; 7. Use of drugs affecting Lp(a) within the specified period before screening or expected to use during the study period; 8. Allergy to oligonucleotide drugs; 9. Received any other clinical study treatment within 3 months prior to screening or within 5 half-lives of the investigational drug; 10. Female participants who are pregnant or breastfeeding at screening, or female / male participants who plan to conceive during the study and within 1 year after the last dose.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage change in Lp(a) from baseline to Day 60~180 | Day 60~180 |
Secondary
| Measure | Time frame |
|---|---|
| Percentage change in Lp(a) from baseline to Day 30~540 | Day 30~540 |
| The percentage of participants achieving Lp(a) < 125 nmol/L and <75 nmol/L. | Day 30~540 |
| Changes of LDL-C from baseline to Day 30~540 | Day 30~540 |
| Changes of ApoB from baseline to Day 30~540 | Day 30~540 |
| Incidence of TEAEs during the treatment | During treatment |
| ADA incidence | During treatment |
| The plasma concentration of SYH2068. | During treatment |
Contacts
CONTACTClinical Trials Information Group officer
Outcome results
None listed